Fate Therapeutics (FATE) Stock Forecast & Price Target

Compare

1,254 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FATE Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Fate

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FATE Stock 12 Month Forecast

Average Price Target

$5.29

▲(451.04% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $5.29 with a high forecast of $8.00 and a low forecast of $2.00. The average price target represents a 451.04% change from the last price of $0.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.566153846153846,2.102307692307692,2.638461538461538,3.174615384615384,3.7107692307692304,4.246923076923077,4.783076923076923,5.319230769230769,5.855384615384615,6.391538461538461,6.927692307692308,7.463846153846153,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.3576923076923078,1.6853846153846153,2.013076923076923,2.3407692307692307,2.668461538461538,2.996153846153846,3.323846153846154,3.651538461538461,3.979230769230769,4.306923076923077,4.634615384615384,4.962307692307692,{"y":5.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.1046153846153846,1.1792307692307693,1.2538461538461538,1.3284615384615384,1.403076923076923,1.4776923076923076,1.5523076923076924,1.626923076923077,1.7015384615384614,1.7761538461538462,1.8507692307692307,1.9253846153846155,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$8.00

Average Price Target$5.29

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Martin Fan

Wedbush

Buy

629.17%

Upside

Reiterated

12/09/25

Fate Therapeutics (FATE) Gets a Buy from Wedbush

Tazeen Ahmad

Bank of America Securities

Hold

108.33%

Upside

Assigned

11/17/25

Fate Therapeutics (FATE) Receives a Hold from Bank of America SecuritiesFATE, Neutral, $2 PO ... We reiterate our Neutral rating with $2 PO.

Salim Syed

Mizuho Securities

Buy

733.33%

Upside

Reiterated

11/14/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), ALX Oncology Holdings (NASDAQ: ALXO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)

Tara Bancroft

TD Cowen

―

Hold

―

Reiterated

11/13/25

Fate Therapeutics: Balancing Potential and Uncertainty with FT819's Promise in Autoimmune Treatment

Gil Blum

Needham

―

Hold

―

Reiterated

11/13/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (NASDAQ: INDP) and Fate Therapeutics (NASDAQ: FATE)we maintain our Hold rating

Robert Burns

H.C. Wainwright

Buy

420.83%

Upside

Upgraded

10/31/25

Fate Therapeutics upgraded to Buy from Neutral at H.C. WainwrightFate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Peter Lawson

Barclays

Buy

108.33%

Upside

Reiterated

10/28/25

Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)

Edward Tenthoff

Piper Sandler

Buy

525.00%

Upside

Reiterated

10/27/25

Piper Sandler Keeps Their Buy Rating on Fate Therapeutics (FATE)

Daina Graybosch

Leerink Partners

$12→$7

Buy

629.17%

Upside

Reiterated

09/04/25

Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE)

Yanan Zhu

Wells Fargo

$4→$2.5

Hold

160.42%

Upside

Reiterated

08/13/25

Fate Therapeutics price target lowered to $2.50 from $4 at Wells FargoFate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

05/14/25

Oppenheimer Sticks to Its Hold Rating for Fate Therapeutics (FATE)

Jack Allen

Robert W. Baird

$5→$4

Hold

316.67%

Upside

Reiterated

05/14/25

Fate Therapeutics (FATE) PT Lowered to $4 at BairdBaird analyst Jack Allen lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $4.00 (from $5.00) while maintaining a Neutral rating.

Michael Ulz

Morgan Stanley

Hold

420.83%

Upside

Reiterated

03/06/25

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties

Michael Yee

Jefferies

$10→$8

Buy

733.33%

Upside

Reiterated

03/06/25

Fate Therapeutics (FATE) PT Lowered to $8 at JefferiesJefferies analyst Michael Yee lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $10.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Martin Fan

Wedbush

Buy

629.17%

Upside

Reiterated

12/09/25

Fate Therapeutics (FATE) Gets a Buy from Wedbush

Tazeen Ahmad

Bank of America Securities

Hold

108.33%

Upside

Assigned

11/17/25

Fate Therapeutics (FATE) Receives a Hold from Bank of America SecuritiesFATE, Neutral, $2 PO ... We reiterate our Neutral rating with $2 PO.

Salim Syed

Mizuho Securities

Buy

733.33%

Upside

Reiterated

11/14/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), ALX Oncology Holdings (NASDAQ: ALXO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)

Tara Bancroft

TD Cowen

―

Hold

―

Reiterated

11/13/25

Fate Therapeutics: Balancing Potential and Uncertainty with FT819's Promise in Autoimmune Treatment

Gil Blum

Needham

―

Hold

―

Reiterated

11/13/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (NASDAQ: INDP) and Fate Therapeutics (NASDAQ: FATE)we maintain our Hold rating

Robert Burns

H.C. Wainwright

Buy

420.83%

Upside

Upgraded

10/31/25

Fate Therapeutics upgraded to Buy from Neutral at H.C. WainwrightFate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Peter Lawson

Barclays

Buy

108.33%

Upside

Reiterated

10/28/25

Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)

Edward Tenthoff

Piper Sandler

Buy

525.00%

Upside

Reiterated

10/27/25

Piper Sandler Keeps Their Buy Rating on Fate Therapeutics (FATE)

Daina Graybosch

Leerink Partners

$12→$7

Buy

629.17%

Upside

Reiterated

09/04/25

Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE)

Yanan Zhu

Wells Fargo

$4→$2.5

Hold

160.42%

Upside

Reiterated

08/13/25

Fate Therapeutics price target lowered to $2.50 from $4 at Wells FargoFate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

05/14/25

Oppenheimer Sticks to Its Hold Rating for Fate Therapeutics (FATE)

Jack Allen

Robert W. Baird

$5→$4

Hold

316.67%

Upside

Reiterated

05/14/25

Fate Therapeutics (FATE) PT Lowered to $4 at BairdBaird analyst Jack Allen lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $4.00 (from $5.00) while maintaining a Neutral rating.

Michael Ulz

Morgan Stanley

Hold

420.83%

Upside

Reiterated

03/06/25

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties

Michael Yee

Jefferies

$10→$8

Buy

733.33%

Upside

Reiterated

03/06/25

Fate Therapeutics (FATE) PT Lowered to $8 at JefferiesJefferies analyst Michael Yee lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $10.00) while maintaining a Buy rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fate Therapeutics

1 Month

xxx

Success Rate

12/30 ratings generated profit

Average Return

-2.01%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -2.01% per trade.

3 Months

xxx

Success Rate

13/30 ratings generated profit

Average Return

+0.49%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 43.33% of your transactions generating a profit, with an average return of +0.49% per trade.

1 Year

Daina GrayboschLeerink Partners

Success Rate

8/30 ratings generated profit

Average Return

-17.55%

reiterated a buy rating 3 months ago

Copying Daina Graybosch's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -17.55% per trade.

2 Years

xxx

Success Rate

5/30 ratings generated profit

Average Return

-48.15%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -48.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FATE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FATE has received 6 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. FATE average Analyst price target in the past 3 months is 5.29.

Each month's total comprises the sum of three months' worth of ratings.

FATE Financial Forecast

FATE Earnings Forecast

Next quarter’s earnings estimate for FATE is -$0.27 with a range of -$0.30 to -$0.24. The previous quarter’s EPS was -$0.27. FATE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year FATE has Performed in-line its overall industry.

FATE Sales Forecast

Next quarter’s sales forecast for FATE is $1.25M with a range of $0.00 to $3.00M. The previous quarter’s sales results were $1.74M. FATE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year FATE has Performed in-line its overall industry.

FATE Stock Forecast FAQ

What is FATE’s average 12-month price target, according to analysts?

Based on analyst ratings, Fate Therapeutics Inc’s 12-month average price target is 5.29.

What is FATE’s upside potential, based on the analysts’ average price target?

Fate Therapeutics Inc has 451.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FATE a Buy, Sell or Hold?

Fate Therapeutics Inc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Fate Therapeutics Inc’s price target?

The average price target for Fate Therapeutics Inc is 5.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $2.00. The average price target represents 451.04% Increase from the current price of $0.96.

What do analysts say about Fate Therapeutics Inc?

Fate Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of FATE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Fate Therapeutics (FATE) Stock Forecast & Price Target

FATE Analyst Ratings

FATE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fate Therapeutics

FATE Analyst Recommendation Trends

FATE Financial Forecast

FATE Earnings Forecast

FATE Sales Forecast

FATE Stock Forecast FAQ

Detailed List of Analyst Forecasts